



MindWalk™

IPA, BioStrand, and Talem are now MindWalk

MindWalk™ (NASDAQ: HYFT)



Where biology becomes computable

Bio-Native AI engineered to reason
the way biology stores meaning

February 2026

The Problem

Drug discovery often fails not because we lack data—but because biology encodes information in ways AI cannot interpret.

- + Biological data is fragmented across silos
- + Structure, function, and outcome relationships are obscured
- + Most AI models rely on pattern prediction, not **biological reasoning**
- + This can lead to **slow cycles**, **higher cost**, and **clinical risk**



The Breakthrough


The missing layer: computable biology for drug discovery

Patented Bio-Native LensAI™, powered by HYFT® technology, is engineered to reason how biology stores meaning across sequence, structure, function, and evolutionary constraint.

This becomes a unified representation of biology you can:

- + Compare across targets and programs
- + Reason over to understand mechanism and risk
- + Engineer against to refine candidates

Not generative guessing. Biological reasoning.



The Platform

LensAI™ Platform

→ The Reasoning & Design Layer

Interrogates data knowledge graph to uncover **mechanisms, epitopes, immunogenic signals, and design rules**


Powered by HYFT® Technology

→ The Representation Layer

Transforms raw biological data into a **connected, interpretable graph**

Together, they help make therapeutic discovery:

Faster + More Precise + More Scalable




What this enables

Capabilities

- + **Target / epitope identification** with mechanistic clarity
- + **Immunogenicity assessment** before wet-lab investment
- + **De-risking** molecule design and optimization
- + **Ability to evaluate, refine, and select candidates** in hours


This is **the shift from experimental exploration**
→ **computational reasoning**



Outcome: what this changes

Outcome:

- + Supporting higher probability of clinical success
- + Meaningful compression of discovery timelines
- + Improved capital efficiency across therapeutic programs



Why it's different

We do not force AI onto biology.
We build AI that works like biology.

- + **Bio-native representations**, not tokenization
- + **Causal reasoning**, not correlations
- + **Unified biological graph**, not siloed datasets
- + **Actionable designs**, not black-box outputs
- + **Validated in real therapeutic programs**



The Vault

A portfolio of AI-evolved assets built to support high-incidence and high-burden diseases.

Assets include: Antibodies, Vaccines, and Peptides

Vaccine asset: Influenza

Using its patented HYFT® technology, MindWalk identified a functional pattern in influenza biology that remains intact despite surface-level genetic change.

Across key influenza variants:

Influenza A in human datasets, including H3N2 and H3N2 subclade K

Influenza A in avian datasets, spanning subtypes H5, H7, and H9

Influenza A in swine-associated datasets, including H1N1

Influenza B across both Victoria and Yamagata lineages

This pattern reflects a shared evolutionary constraint, not a strain-specific or sequence-dependent feature.



Additional Vault asset highlights

GLP-1 Dual-Pathway (longevity & metabolic resilience)

LensAI™ uncovered a **synergistic pathway** that extends GLP-1 effects from **weight loss** toward **cellular resilience and health span**.

Positioning:

The next generation of GLP-1 therapeutics—shifting from symptom management **to biological restoration**.

Universal Dengue Vaccine (advancing through preclinical development & testing)

HYFT® technology identified a **structurally conserved epitope** shared across all four dengue serotypes.

This enables a **single vaccine construct with broad and durable protection**—solving a problem that hindered decades of dengue vaccine.

Positioning:

A rational epitope-first dengue vaccine designed to minimize enhancement risk.

Market fit

Pharma wants:

- + Better targets
- + Better designed molecules
- + Lower risk of failure

MindWalk provides the **infrastructure layer** that helps them achieve it.



Biology is becoming computable— **MindWalk is built to compute it.**

Market opportunity

Unlocking scalable revenue with Bio-AI

Total Addressable Market (TAM):

- + AI in drug discovery: \$50B+ projected TAM by 2030
- + Biological data infrastructure (bio-native AI + data harmonization) key growth vertical
- + Life sciences data management: multi-\$B market (Informatica ~25% share; \$445M/qtr)

Our vertical SaaS opportunity:

- + HYFT-powered data management and LensAI's AI modules
- + Scalable subscription models
- + Tiered API access, usage-based pricing, upsell to custom modules
- + >3,000 antibody programs since 2020
- + Targeted SaaS rollout to existing wet-lab clients, including 19 of the top 20 global pharma

Strategic market goals

- + Focused on high-growth AI drug discovery segments
- + Select partnerships in key therapeutic areas to validate and expand platform adoption
- + Building recurring revenue through pilot programs, renewals, and modular platform offerings

Business model

Hybrid platform + co-development upside

Revenue Stream	Description
Enterprise Access (SaaS)	Platform subscriptions & secured cloud access
Usage-Based Compute / API	High-throughput inference and screening
Data Onboarding	Conversion of proprietary datasets into HYFT graph format
Co-Development & Drug Economics	Upfronts + milestones + royalties on resulting assets

LensAI™ unique competitive advantage

It stores biological meaning, not just data

Next-generation storage architecture

LensAI is the only AI platform designed to encode biological semantics directly at the storage layer.

- + **Native biological queries:** Direct homology search on stored fingerprints
- + **Real-time intelligence:** Immediate biological reasoning
- + **Inherent relationships:** 660M objects across 25B+ native links
- + **Unified omics language:** Sequence, structure, function and literature linked automatically

How competitors store biological data

Palantir: Semantic layers above storage; sequences stored as generic strings

Microsoft Fabric: Delta Lake format treats DNA/protein as text blobs

Snowflake: Cloud-native but biological sequences remain as VARCHAR fields

Databricks: ACID transactions but requires external bioinformatics tools

Validation

- + Used by teams across **19 of the top 20 global pharma companies**
- + **Dengue vaccine** now preclinical
- + **GLP-1 dual-pathway program** advancing toward development milestones
- + **AMD partnership** accelerating compute scaling

The technology is **de-risked, validated, and expanding**

Reprogramming drug discovery

The future of AI-driven biology

Partnering with top tech:

AMD

powered by
aws

InterSystems™

VULTR

AMD X VULTR X MindWalk life science case study series

Reprogramming Discovery: How AMD GPUs Are
Powering the Next Wave of AI-Driven Biology

Part 1

Embeddings for NLP in
Life Sciences

Reprogramming Discovery: How AMD GPUs Are
Powering the Next Wave of AI-Driven Biology

Part 2


Protein Embeddings for Enhanced
Biological Analysis

Reprogramming Discovery: How AMD GPUs Are
Powering the Next Wave of AI-Driven Biology

Part 3

RFdiffusion – Advancing De Novo
Protein Design

Leadership



Jennifer Bath, Ph.D.
Chief Executive Officer

Visionary executive in biotechnology and therapeutics, specializing in therapeutic and prophylactic drug development, AI-driven biologics, and infectious disease. Spearheads LensAI's industry leadership in next-generation drug discovery.



R. Scott Areglado
Chief Financial Officer

Seasoned finance leader with 30+ years in accounting and 15+ years in healthcare space, including FPR roles at BrainsWay and iCad. Brings deep public-company, M&A, and capital-markets experience to scale the business.



Frédéric Chabot
Head of Corporate Development

Business strategist with deep expertise in biotech investments, AI-driven market expansion, and corporate finance. Drives strategic partnerships and industry adoption of LensAI and HYFT OS.



Thomas Lynch, PhD
Chief Business Officer

Biopharma commercial executive with a Ph.D. in biochemistry and NCI-funded research background. Built and led global sales, technical, and client teams at Aldeveron, driving revenue growth, strategic accounts, and market-aligned launches across omics and CDMO services.



Ingrid Brands, MD, Ph.D.
Chief Innovation and Strategy Officer

Experienced leader in biotech operations and strategic growth, ensuring seamless execution of AI-powered discovery and laboratory integration. Expertise in data-driven decision-making and process optimization.



Dirk Van Hyfte, MD, Ph.D.
Chief Technology Officer

Pioneering expert in AI-driven drug discovery and computational biology, leading the integration of HYFT technology with large-scale AI models. Passionate about solving the Information Integration Dilemma (IID) in biotechnology.

Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of MindWalk Holdings Corp. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements (within the meaning of applicable securities laws) to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including but not limited to: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Please see the Company’s most recent Annual Information Form, which is available under the Company’s profile on EDGAR at www.sec.gov/edgar and SEDAR+ at www.sedarplus.ca for additional related risks factors that could materially affect the Company’s operations and financial results.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise accept as required by applicable securities. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

MindWalk™ (NASDAQ: HYFT)

Where Biology Becomes Computable

Bio-Native AI engineered to reason the way biology stores meaning.



Thanks

**Corporate
Executive
Headquarters:**

823 Congress Ave,
Suite 300
Austin, Texas 78701
USA

Contact: investors@mindwalk.com
mindwalkAI.com